+39%

est. 2Y upside i

HealthcareIPO

Rank

#2376

Sector

Healthcare SaaS / Vertical Software

Est. Liquidity

~0Y

Data Quality

Data: Medium

Weave at $4.78 (~1.3x revenue) is a deep value play with 72% GM, FCF positive, and AI receptionist catalyst.

Last updated: March 21, 2026

Bull (30%)+100%

TrueLark AI receptionist drives NRR >105%. Revenue to $300M+. Stock re-rates to 3-4x rev ($9-12).

Base (45%)+40%

17% growth sustains. AI adds incremental ARPU. Stock to $6.70. Analyst target $11.

Bear (25%)-35%

NRR stays below 100. Unprofitable. Dental market saturates. Stock to $3.

Est. time to liquidity~0.0 years

Preference Stack Risk

low

Public — no preference stack.

Dilution Risk

moderate

SBC dilution; may need equity raise if unprofitable.

Secondary Liquidity

active

NYSE-listed (WEAV).

Other — 12 roles

View all 12 open roles at Weave →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Weave's data — designed to show you've done your homework.

  • 1

    “TrueLark adoption rate and NRR impact?”

  • 2

    “Path to NRR >100%?”

  • 3

    “New vertical expansion (medical, PT)?”

Community

Valuation Sentiment

Our model estimates +39% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.